Gene

LYN

LYN proto-oncogene, Src family tyrosine kinase

Explore in graph →CI-GENE-00011728HGNC:6735 ENSG00000254087 NCBI 4067 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (9)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–9 of 9 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
LYN Mutation1
(oncogenic)	Diffuse Large B-Cell LymphomaCURATED_BROADER	Oncogenic	E	Supports Oncogenicity	2	submitted

Cohorts

Alteration frequency by cohort (19)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved19 cohort rows · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Colorectal Cancer (MSK, Cancer Discovery 2022) coadread_mskresistance_2022	Colorectal Adenocarcinoma	Ssm	7

Literature

Linked publications (4)

25 per page, newest first.

pubmedPublishedShowing 1–4 of 4 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group.
· Blood · 2017 · PMID 28408464 · validated civic_curation pubmed
Characterization of pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia with kinase fusions in Japan.
· Blood Cancer J · 2016 · PMID 27176795 · validated civic_curation pubmed
Rapid Molecular Response to Dasatinib in a Pediatric Relapsed Acute Lymphoblastic Leukemia With NCOR1-LYN Fusion.
· Front Oncol · 2020 · PMID 32266142 · validated civic_curation pubmed
Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines.
· Leuk Res · 2008 · PMID 18191450 · validated civic_curation

LYN OVEREXPRESSION3
Bafetinib + DasatinibSubstitutes	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Does Not Support Resistance	3	accepted	EID7874 The BCR-ABL1 expressing imatinib-resistant cell line MYL-R overexpresses LYN, an SRC family kinase. Dasatinib showed the most potency against MYL-R compared to the non-resistant MYL cell line (IC50: 6… (full text at CIViC) PMID 18191450 · Deguchi et al., 2008 · Open in CIViC	civic
Dasatinib	Malignant NeoplasmALIAS	Predictive	D	Does Not Support Resistance	3	rejected	EID9085 The BCR-ABL1 expressing imatinib-resistant cell line MYL-R overexpresses LYN, an SRC family kinase. Dasatinib exhibited similar potency against MYL-R (IC50: 6.4 nM) as compared to MYL cell lines (IC50… (full text at CIViC) PMID 18191450 · Deguchi et al., 2008 · Open in CIViC	civic
Nilotinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Resistance	1	accepted	EID7875 The BCR-ABL1 expressing imatinib-resistant cell line MYL-R overexpresses LYN, an SRC family kinase. Nilotinib showed 3.1 times less potency than bafetinib (INNO-406) against MYL-R (IC50: 993.6 nM vs. … (full text at CIViC) PMID 18191450 · Deguchi et al., 2008 · Open in CIViC	civic

LYN OVEREXPRESSION3

Bafetinib + DasatinibSubstitutes

Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS

Predictive

Does Not Support Resistance

accepted

EID7874

The BCR-ABL1 expressing imatinib-resistant cell line MYL-R overexpresses LYN, an SRC family kinase. Dasatinib showed the most potency against MYL-R compared to the non-resistant MYL cell line (IC50: 6… (full text at CIViC)

PMID 18191450 · Deguchi et al., 2008 · Open in CIViC

civic

Dasatinib

Malignant NeoplasmALIAS

Predictive

Does Not Support Resistance

rejected

EID9085

The BCR-ABL1 expressing imatinib-resistant cell line MYL-R overexpresses LYN, an SRC family kinase. Dasatinib exhibited similar potency against MYL-R (IC50: 6.4 nM) as compared to MYL cell lines (IC50… (full text at CIViC)

PMID 18191450 · Deguchi et al., 2008 · Open in CIViC

civic

Nilotinib

Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS

Predictive

Supports Resistance

accepted

EID7875

The BCR-ABL1 expressing imatinib-resistant cell line MYL-R overexpresses LYN, an SRC family kinase. Nilotinib showed 3.1 times less potency than bafetinib (INNO-406) against MYL-R (IC50: 993.6 nM vs. … (full text at CIViC)

PMID 18191450 · Deguchi et al., 2008 · Open in CIViC

civic

LYN Y508F2
Axitinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Sensitivity Response	—	submitted	EID4804 In an in vitro study, a K562 cell line expressing LYN Y508F mutation demonstrated sensitivity to axitinib treatment, comparable to K562 cells expressing wild-type LYN or vector. Sensitivity was determ… (full text at CIViC) PMID 26912052 · Halbach et al., 2016 · Open in CIViC	civic
Dasatinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Sensitivity Response	3	submitted	EID4805 In an in vitro study, a K562 cell line expressing LYN Y508F mutation demonstrated sensitivity to dasatinib treatment, comparable to K562 cells expressing wild-type LYN or vector. Sensitivity was deter… (full text at CIViC) PMID 26912052 · Halbach et al., 2016 · Open in CIViC	civic

LYN Y508F2

Axitinib

Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS

Predictive

Supports Sensitivity Response

—

submitted

EID4804

In an in vitro study, a K562 cell line expressing LYN Y508F mutation demonstrated sensitivity to axitinib treatment, comparable to K562 cells expressing wild-type LYN or vector. Sensitivity was determ… (full text at CIViC)

PMID 26912052 · Halbach et al., 2016 · Open in CIViC

civic

Dasatinib

Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS

Predictive

Supports Sensitivity Response

submitted

EID4805

In an in vitro study, a K562 cell line expressing LYN Y508F mutation demonstrated sensitivity to dasatinib treatment, comparable to K562 cells expressing wild-type LYN or vector. Sensitivity was deter… (full text at CIViC)

PMID 26912052 · Halbach et al., 2016 · Open in CIViC

civic

LYN Fusion3
(diagnostic)	B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like	Diagnostic	C	Supports Positive	3	accepted	EID12801 In this 2017 study, the authors characterized 284 cases of Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL) identified from a cohort of 1,389 pediatric patients with high-risk B… (full text at CIViC) PMID 28408464 · Reshmi et al., 2017 · Open in CIViC	civic
〃	B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like	Diagnostic	C	Supports Positive	3	accepted	EID12802 This retrospective Japanese multicenter study investigated kinase-activating gene fusions in pediatric B-lymphoblastic leukemia (B-ALL) lacking recurrent cytogenetic abnormalities, with the goal of de… (full text at CIViC) PMID 27176795 · Imamura et al., 2016 · Open in CIViC	civic
〃	B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like	Diagnostic	C	Supports Positive	3	accepted	EID12809 In this 2020 case report, the authors present a pediatric patient with relapsed B-lymphoblastic leukemia (B-ALL), providing critical evidence for the diagnostic and therapeutic role of LYN fusions. Th… (full text at CIViC) PMID 32266142 · Dai et al., 2020 · Open in CIViC	civic

LYN Fusion3

(diagnostic)

B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like

Diagnostic

Supports Positive

accepted

EID12801

In this 2017 study, the authors characterized 284 cases of Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL) identified from a cohort of 1,389 pediatric patients with high-risk B… (full text at CIViC)

PMID 28408464 · Reshmi et al., 2017 · Open in CIViC

civic

〃

B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like

Diagnostic

Supports Positive

accepted

EID12802

This retrospective Japanese multicenter study investigated kinase-activating gene fusions in pediatric B-lymphoblastic leukemia (B-ALL) lacking recurrent cytogenetic abnormalities, with the goal of de… (full text at CIViC)

PMID 27176795 · Imamura et al., 2016 · Open in CIViC

civic

〃

B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like

Diagnostic

Supports Positive

accepted

EID12809

In this 2020 case report, the authors present a pediatric patient with relapsed B-lymphoblastic leukemia (B-ALL), providing critical evidence for the diagnostic and therapeutic role of LYN fusions. Th… (full text at CIViC)

PMID 32266142 · Dai et al., 2020 · Open in CIViC

civic